Prognostic significance of HER-2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3851-3855

  Jana, Debarshi ^a   Mandal, Syamsundar ^b   Mukhopadhyay, Madhumita ^a   Mitra, Debabrata ^c   Mukhopadhyay, Sunit K ^d   Sarkar, Diptendra Kumar ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^c MEDICAL COLLEGE AND HOSPITAL   (India)

^d WEST BENGAL UNIVERSITY OF ANIMAL AND FISHERY SCIENCES   (India)

Author keywords

Breast cancer; Follow up Eastern India; HER 2 neu; Prognosis; Survival

Indexed keywords

EID: 84873645874     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3851     Document Type: Article

References (24)

1. Albergaria A, Ricardo S, Milanezi F, et al. (2011) Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer, 11, 299.
2. Borg A, Tandon AK, Sigurdsson H, et al. (1990). HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res, 50, 4332-7.
3. Carter CL, Allen C, Henson D. (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63, 181-7.
4. Chia S, Norris B, Speers C, et al. (2008). Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol, 26, 5697-704.
5. Cooke T, Reeves J, Lanigan A, Stanton P. (2001). HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol, 12, 23-8.
6. Dawood S, Broglio K, Buzdar AU, et al. (2010). Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an Institutional-Based Review. J Clin Oncol, 28, 92-8.
7. Ferlay J BF, Pisani P, Parkin DM,. (2000). Cancer Incidence, Mortality and Prevalence Worldwide. Globocan, Version 1.0.
8. Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM. (2008). Cancer Incidence and Mortality Worldwide. Globocan, Version 1.2
9. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. (2010). High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, nodenegative tumors 1 cm or smaller. J Clin Oncol, 27, 5700-6.
10. Gullick WJ, Srinivasan R. (1998). The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat, 52, 43-53.
11. Henson DE, Ries L, Freedman LS, Carriaga M. (1991). Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer, 68, 2142-9.
12. Laguens G, Coronato S, Di Girolamo W. (2006). Biomarkers in breast cancer. CEJMed, 1, 330-47.
13. Nguyen PL, Taghian AG, Katz MS, et al. (2009). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol, 26, 2373-8.
14. Payne SLJ, Bowen RL, Jones JL, Wel CA. (2008). Predictive markers in breast cancer - the present. Histopathology, 52, 82-90.
15. Rakkhit R, Broglio K, Peintinger F, et al. (2009). Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. Cancer Res, 69, 701.
16. Sen U, Sankaranarayanan R, Mandal S, et al. (2002). Cancer patterns in eastern India: The first report of the Kolkata Cancer Registry. Int J Cancer, 100, 86-91.
17. Slamon DJ, Clark GM, Wong SG, et al. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
18. Slamon DJ, Godolphin W, Jones LA, et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
19. Taneja P, Maglic D, Kai F, et al. (2010). Classical and novel prognostic markers for breast cancer and their clinical significance. Oncology, 4, 15-34.
20. Tovey SM, Brown S, Doughty JC, et al. (2009). Poor survival outcomes in HER2-positive breast cancer patients with lowgrade, node-negative tumours. Bri J Cancer, 100, 680-3.
21. Tsuda H, Hirohashi S, Shimosato Y, et al. (1989). Correlation between long term survival in breast cancer patients and amplification of two putative oncogene co-amplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res, 49, 3104-8.
22. Van Belle V, Decock J, Hendrickx W, et al. (2011). Short-term Prognostic Index for Breast Cancer: NPI or Lpi. Pathology Research International, 918408, 7 pages.
23. Witton CJ, Reeves JR, Going JJ, Cooke TG. (2003). Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 200, 290-7.
24. Wülfing P, Borchard J, Buerger H, et al. (2006). HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res, 12, 1715-20